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Adalimumab Reduces 
Photoreceptor Cell Death in 
A Mouse Model of Retinal 
Degeneration
Cristina Martínez-Fernández de la Cámara1, Alberto M Hernández-Pinto2, Lorena Olivares-
González1,3, Carmen Cuevas-Martín3,4, María Sánchez-Aragó3,4, David Hervás5, 
David Salom6, José M. Cuezva3,4, Enrique J de la Rosa2, José M Millán1,3,7 & 
Regina Rodrigo1,3
Growing evidence suggests that inflammation is involved in the progression of retinitis pigmentosa 
(RP) both in patients and in animal models. The aim of this study was to investigate the effect of 
Adalimumab, a monoclonal anti-TNFα antibody, on retinal degeneration in a murine model of human 
autosomal recessive RP, the rd10 mice at postnatal day (P) 18. In our housing conditions, rd10 retinas 
were seriously damaged at P18. Adalimumab reduced photoreceptor cell death, as determined by 
scoring the number of TUNEL-positive cells. In addition, nuclear poly (ADP) ribose (PAR) content, an 
indirect measure of PAR polymerase (PARP) activity, was also reduced after treatment. The blockade 
of TNFα ameliorated reactive gliosis, as visualized by decreased GFAP and IBA1 immunolabelling 
(Müller cell and microglial markers, respectively) and decreased up-regulation of TNFα gene 
expression. Adalimumab also improved antioxidant response by restoring total antioxidant capacity 
and superoxide dismutase activity. Finally, we observed that Adalimumab normalized energetic 
and metabolic pattern in rd10 mouse retinas. Our study suggests that the TNFα blockade could be 
a successful therapeutic approach to increase photoreceptor survival during the progression of RP. 
Further studies are needed to characterize its effect along the progression of the disease.
Retinitis pigmentosa (RP) is a group of inherited retinal dystrophies characterized by progressive and 
irreversible loss of vision that in most models studied, parallels photoreceptor cell death1–3. RP is the 
leading cause of genetic blindness in adults with an estimated incidence of 1 in 3,500 ~ 4,500 human 
births4. Patients with RP typically loose night vision in adolescence, peripheral vision in young adult-
hood, and central vision later in life, due to progressive, sequential loss of rod and cone photoreceptor 
cells. Although many therapeutic approaches have been developed to prevent photoreceptor cell death, 
no effective treatment is still available. More than 70 genes, including phosphodiesterase 6 (PDE6) subu-
nit genes, have been identified to date whose mutations cause different forms of RP5,6. Besides the genetic 
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defect, evidence suggests that oxidative stress and neuroinflammation contribute to its progression7–9. 
In particular, inflammatory processes including microglial activation and upregulation of inflammatory 
cytokines (TNFα , IL-6, IL-1β , etc.) and chemokines (MCP1, RANTES, etc.) have been described in 
patients as well as in animal models of RP10–12.
Tumor necrosis factor alpha (TNFα ) is a pleiotropic cytokine essential for the induction and main-
tenance of the inflammatory immune responses. It is a well characterized mediator of cellular activities 
including proliferation, survival, differentiation, inflammation and cell death. In the retina, it is likely 
secreted from activated macrophages, astrocytes, microglia and Müller glial cells. TNFα can trigger sev-
eral well-characterized death-promoting (caspase-dependent and caspase-independent cell death) and 
survival-promoting pathways, depending upon the predominating signalling pathway in the particular 
cell type13. In the eye, TNFα appears to have a role in the pathogenesis of inflammatory diseases such 
as uveitis14, as well as in retinal degenerations such as diabetic retinopathy, age-related macular degen-
eration and, recently, in RP11,15–17.
Several anti-TNFα agents (Infliximab, Adalimumab, Etarnecept, Golimumab and Certolizumab 
pegol) have been developed and approved for clinical use in inflammatory diseases such as rheumatoid 
arthritis, psoriasis and ankylosing spondylitis18. These anti-TNFα agents are antibodies against TNFα 
or TNFα receptor. In Ophthalmology, they are widely used as an alternative to traditional immunosup-
pressive treatments in non-infectious uveitis. More recently anti-TNFα agents have been used for retinal 
diseases such as neovascular age-related macular degeneration, diabetic macular edema and retinal vein 
occlusions19–21.
To further explore the in vivo potential benefits of blocking TNFα we adopted the rd10 mouse, a 
model of human autosomal recessive RP. This mouse carries a mutation on the β subunit of the cGMP 
PDE6 gene (Pde6β) that produces retinal degeneration2.
In this study, we first analysed the early stages of retinal degeneration and the profile of TNFα expres-
sion in rd10 mice under our housing conditions. We observed a peak of TNFα gene expression and 
photoreceptor cell death at postnatal day (P) 18. Therefore, we studied the effect of Adalimumab, a mon-
oclonal antibody against TNFα , on the progression of the retinal degeneration at this age. We observed 
that Adalimumab prevented TNFα upregulation, reduced photoreceptor cell death, slowed microglial 
and Müller cell activation, improved antioxidant response and ameliorated the energetic and metabolic 
dysfunction at P18. Based on these results we suggest that anti-TNFα therapies could be promising treat-
ments to improve photoreceptor cell survival in humans with RP. However, further studies are needed 
to investigate the molecular mechanisms involved in the protective effect of anti-TNFα agents and their 
long-term effect.
Results
Temporal progression of retinal degeneration in rd10 mice. Light exposure accelerates progres-
sion of retinal degeneration in many animal models of RP22,23. Hence we first investigated the time course 
of retinal degeneration in rd10 mice from P13 to P20 stabulated under light intensities between 98 and 
131 lux. Sytox Green nuclear staining showed a decline of the number of photoreceptor cell nuclei rows 
in the outer nuclear layer (ONL) in rd10 mice. As expected, we did not find a significant difference 
between control and rd10 mice at P13. But the number of cell nuclei rows in the ONL dropped abruptly 
from eleven to five from P15 to P20 (Fig. 1A). Degeneration was evident at P18 (Fig. 1D).
Then, we assessed photoreceptor cell death by TUNEL staining which detects DNA breaks in both 
apoptotic and necrotic nuclei. From P15 to P20 there was a significant increase of TUNEL-positive cells 
in rd10 mice, reaching a peak at P18 (12.5 ± 2.4 TUNEL-positive cells/normalized ONL area (five-fold 
increase between P15 and P18), Mann-Whitney U test, p < 0.0001) (Fig.  1B,D, and Supplementary 
Table S1).
It has been previously described that TNFα is upregulated in the retina of rd10 mice previous to pho-
toreceptor cell death peak11,24. Therefore, we analysed gene expression of TNFα during the time course of 
retinal degeneration in our housing conditions. As shown in Fig. 1C, TNFα was upregulated from P13 
to P20 with the highest expression at P18 (6.1 ± 1.2 relative expression (six-fold increase over control 
retinas), Mann-Whitney U test, p = 0.0002) concomitantly with the peak of TUNEL-positive cells. At P18 
a significant increase of TNFα protein level was also observed in the retina of rd10 mice (mean = 65.5 
pg/mg protein, confidence interval [25.1–170.9], generalized least squares model, p = 0.0034) compared 
to control retinas (mean = 17.1 pg/mg protein, confidence interval [15.8–18.5]).
In view of these results, P18 was chosen as the end point for the ensuing analysis of the potential 
protective effect of Adalimumab.
Adalimumab reduced photoreceptor cell loss and PARP activation. To determine whether 
Adalimumab treatment protects against photoreceptor cell death, we quantified the normalized ONL 
thickness ratio and the number of rows of nuclei in the ONL at P18. Normalized ONL thickness 
decreased slower in Adalimumab-treated rd10 retinas (reduction of 20% over control retinas) than in 
vehicle-treated rd10 retinas (reduction of 40% over control retinas) (Fig.  2A and Supplementary Table 
S1). A mixed linear model analysis also revealed that Adalimumab significantly reduced (p = 0.047) 
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Figure 1. Time course of retinal degeneration in the rd10 mouse retina. (a) Quantitation of the 
number of rows of photoreceptor nuclei from P13 to P20 in control (C57Bl6) and rd10 mice. (b) Number 
of TUNEL-positive cells by normalized ONL thickness in control and rd10 mice from P15 to P20. (c) 
Relative TNFα gene expression from P13 to P20 in rd10 mice. Values are the mean ± SEM of, at least, five 
retinas per group. Values that are significantly different are indicated by asterisks *p < 0.05, **p < 0.001, 
***p < 0.0001 (Mann-Whitney U test). (d) Photoreceptor cell death was visualized by TUNEL (red) in Sytox 
Green-counterstained in retinal sections from control mice at P18 and from rd10 mice at P15, P18 and P20.
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photoreceptor cell loss (7.6 ± 0.4 number of rows of nuclei in the ONL) compared to vehicle-treated rd10 
retinas (5.9 ± 0.3 number of rows of nuclei in the ONL) (Fig. 2B and Supplementary Table S1).
We previously described that Infliximab, other monoclonal anti-TNFα antibody, significantly reduced 
the number of TUNEL-positive cells in Zaprinast-treated explants of porcine retina25. In the current 
study we observed that intraperitoneal administration of Adalimumab significantly decreased (∼ 78%, 
p = 0.048) the number of TUNEL-positive cells in the ONL at P18 (2.7 ± 0.4 TUNEL-positive cells) com-
pared to vehicle-treated rd10 retinas (12.5 ± 2.4 TUNEL-positive cells) (Fig.  3A,C, and Supplementary 
Table S1). Therefore the blockade of TNFα was preventing photoreceptor cell loss in rd10 mice. However, 
the mechanisms of TNFα -induced cell death remained unclear.
Paquet-Durand et al. (2007) demonstrated non-apoptotic mechanisms involved in photoreceptors 
cell death such as the activation of PARP which led to necroptosis in a similar mouse model of RP26. To 
assess whether TNFα inhibition prevented PARP activation, we visualized the content of PAR polymers 
(an indirect marker for PARP activity) and its retinal location at P18. As shown in Fig. 3B, an intense 
and nuclear PAR staining was found in photoreceptor cells of vehicle-treated rd10 retinas. In contrast, 
Adalimumab substantially decreased (up to 90%, p < 0.001) nuclear PAR staining in photoreceptor cells 
(2.1 ± 0.6 PAR-positive cells), compared to vehicle-treated rd10 retinas (25.1 ± 5.5 PAR-positive cells) 
(Fig.  3C). Taking together these results suggested that Adalimumab could slow down photoreceptor 
cell death through PARP pathway inhibition in rd10 mice. Further studies will be designed to test this 
hypothesis.
Adalimumab reduced reactive gliosis. Chronic microglia activation is associated with various 
neurodegenerative diseases including RP. We investigated whether Adalimumab treatment reduced 
microglial activation in rd10 mouse retinas. Microglial cells were identified by specific labelling with 
Iba1, a microglia/macrophage-specific calcium-binding protein. The level of migration from the inner 
to the outer layers of retina was employed as an indicator of microglial activation. Iba1 immunostaining 
revealed that microglia was located in all layers, especially in outer layers in vehicle-treated rd10 retinas. 
Conversely, after intraperitoneal administration of Adalimumab, microglia was preferentially located in 
the inner layers of the retina. A few microglial cells were observed in the outer plexiform layer but not in 
the ONL in Adalimumab-treated rd10 retinas (Fig. 4A). To quantify microglial behaviour, we performed 
a weighted analysis where values close to 1 indicate a high rate of microglial migration to outer layers. 
Statistical analysis confirmed that microglial activation was reduced (p = 0.006) in Adalimumab-treated 
rd10 retinas (0.28 ± 0.03) compared to vehicle-treated rd10 retinas (0.43 ± 0.02) at P18 (Fig.  4C and 
Supplementary Table S1).
Gliosis commonly involves upregulation of the glial fibrillary acidic protein (GFAP), an intermediate 
filament protein, in Müller glial cells. We also studied whether the blockade of TNFα with Adalimumab 
ameliorates glial activation in rd10 mice. Figure 4B shows that GFAP was upregulated in vehicle-treated 
rd10 retinas (p < 0.001) compared to control retinas. Adalimumab tended to decrease (up to 50%) 
(p = 0.27) GFAP-positive immunolabelling compared to vehicle-treated rd10 retinas at P18 (Fig. 4C).
After evaluating the effect of Adalimumab in prevention of reactive gliosis, we analysed whether 
Adalimumab affected gene expression of the inflammatory mediators TNFα and IL-6 by real time PCR at 
P18. After Adalimumab treatment, TNFα expression was significantly reduced (p = 0.006) (Fig. 4C and 
Supplementary Table S1). At P18 we did not observe changes in IL-6 expression neither in vehicle-treated 
rd10 retinas nor in Adalimumab-treated rd10 retinas (data not shown).
Figure 2. Adalimumab administration decreased photoreceptor cell loss in the rd10 mouse retina at 
P18. Bar graph illustrates the effect of Adalimumab (ADA) on normalized ONL thickness (a) and number 
of rows of nuclei in the ONL (b) Values are the mean ± SEM of six retinas per group. Values that are 
significantly different are indicated by asterisks *p < 0.05, ***p < 0.001 (Mixed linear model analysis).
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Adalimumab ameliorated energetic and metabolic dysfunction. It has been described a coor-
dinated downregulation of several metabolic pathways at the onset of retinal degeneration, affecting 
amino acid biosynthesis, glycerol phospholipid metabolism and oxidative phosphorylation in 14-d-old 
Rh1P37H retinas, a Drosophila model expressing the equivalent of the most common RP-linked muta-
tion, RhoP23H27. First, we assessed whether rd10 mice presented a deregulated expression of enzymes 
of energy metabolism and mitochondrial structure and dynamics at P18 by quantitative reverse phase 
protein microarrays (RPPM)28 using validated antibodies (Supplementary Figure S1). We analysed the 
expression of proteins of glycolysis (GAPDH, LDHA), electron transport and oxidative phosphorylation 
(OXPHOS) (NDUFS3, SDHB, CORE 2, COXII and β -F1-ATPase), mitochondrial structure (HSP60) and 
dynamics (OPA1), β -oxidation (HADHA), the pentose phosphate pathway (G6PDH), the antioxidant 
response (SOD1, SOD2 and catalase) and the expression of β -actin as reference protein (Supplementary 
Figure S1).
At the onset of RP, the expression of most of these markers was significantly downregulated in reti-
nas of rd10 mice leading to a global energy depletion that might contribute to cell death (Table 1). No 
significant differences in β -actin were found between control (0.64 ± 0.05 arbitrary units (a.u.)/ng total 
protein) and rd10 retinas (0.71 ± 0.06 a.u./ng total protein). Hence we observed an energy depletion 
and mitochondrial dysfunction during photoreceptor cell death. As shown in Table  1, intraperitoneal 
administration of Adalimumab significantly ameliorated this phenotype in retinas from rd10 mice at P18.
Figure 3. Adalimumab significantly reduced photoreceptor cell death in the rd10 mouse retina at P18. 
Representative photomicrographs of retinal sections showing (a) TUNEL-stained sections revealing dead 
photoreceptors in DAPI-counterstained and (b) PAR content in DAPI-counterstained retinal sections. (c) 
Bar graph illustrates the effect of Adalimumab (ADA) on the number of TUNEL-positive nuclei and PAR-
positive cells. Values are the mean ± SEM of, at least, five retinas in each group. Values that are significantly 
different are indicated by asterisks *p < 0.05, **p < 0.01, ***p < 0.001 (Mixed linear model analysis).
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Adalimumab improved antioxidant response. It has been reported that inflammatory processes 
and oxidative stress are closely linked in several pathologies. The contribution of oxidative damage to 
cell death in rd10 mouse retinas has been previously described29–31. In particular, anti-TNFα treatments 
have been demonstrated to have a positive effect on improving antioxidant response and reducing the 
Figure 4. Adalimumab ameliorated reactive gliosis in the rd10 mouse retina at P18. Representative 
photomicrographs of retinal sections showing (a) Iba1-labelling to visualize microglial cells and (b) GFAP 
content in DAPI-counterstained sections. (c) Bar graph illustrates the effect of Adalimumab (ADA) on 
migration index of microglia, the corrected fluorescence of GFAP content and TNFα gene expression. 
Values are the mean ± SEM of, at least, five retinas per group. Values that are significantly different are 
indicated by asterisks **p < 0.01, ***p < 0.001 (Mixed linear model analysis).
Protein C rd10 rd10 ADA
OXPHOS
NDUFS3 3.1 ± 0.1 1.5 ± 0.2* 2.4 ± 0.2a
SDHB 2.1 ± 0.1 1.3 ± 0.1* 2.1 ± 0.2a
CORE2 1.4 ± 0.1 0.8 ± 0.1* 1.3 ± 0.1a
COX II 2.0 ± 0.1 0.9 ± 0.1* 2.1 ± 0.2a
Β-F1 1.6 ± 0.1 0.9 ± 0.1* 1.8 ± 0.1a
Glycolysis
GADPH 2.0 ± 0.2 1.2 ± 0.1* 2.1 ± 0.2a
LDHA 0.70 ± 0.02 0.34 ± 0.04* 0.60 ± 0.05a
Pentose phosphate pathway G6PDH 0.48 ± 0.04 0.36 ± 0.05* 0.64 ± 0.07a
β -oxidation HADHA 0.34 ± 0.02 0.17 ± 0.01* 0.37 ± 0.03a
Mitochondrial dynamics OPA1 1.9 ± 0.1 1.0 ± 0.1* 1.8 ± 0.2a
Mitochondrial structure HSP60 0.13 ± 0.01 0.05 ± 0.01* 0.14 ± 0.01a
Table 1.  Summary of proteomic changes in rd10 mice with or without Adalimumab. Note: Values are 
expressed as the mean ± SEM of fluorescence intensity (arbitrary units) per ng of total protein of six retinas 
per group. Values that are significantly different from C57Bl6 (C) are indicated by asterisks *p < 0.05. ‘a’ 
represent statistical differences (p < 0.05) between rd10 and rd10 ADA (One way ANOVA, Newman-Keuls 
post-test). ADA: Adalimumab.
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production of reactive oxygen species (ROS) in several pathological situations32. Anti-TNFα antibod-
ies decrease cytokine concentrations, thus directly influencing ROS/RNS production by inflammatory 
cells or indirectly modulate ROS-stimulated signalling pathways activity. Therefore we evaluated whether 
Adalimumab improved the antioxidant response in retinas from rd10 mice. For this purpose, we meas-
ured the total antioxidant capacity (TAC), enzymatic activity of superoxide dismutase (SOD) and catalase 
(CAT) which play a major role in the first line of antioxidant defence.
The TAC was reduced (p = 0.031) in vehicle-treated rd10 retinas (92.6 ± 7.8 nmol of Trolox/mg pro-
tein) compared to control retinas (119 ± 5.7 nmol of Trolox/mg protein). Adalimumab significantly 
increased TAC to 204.5 ± 11.6 nmol of Trolox/mg protein (p < 0.001) (Fig. 5A and Supplementary Table 
S1).
Total SOD activity seemed to decrease (p = 0.12) in vehicle-treated rd10 retinas (25 ± 1 U/mg protein) 
compared to control retinas (33 ± 2 U/mg protein). However, Adalimumab-treated rd10 retinas showed 
higher values of total SOD activity (p = 0.042), being similar to control retinas (36 ± 4 U/mg protein) 
(Fig. 5A and Supplementary Table S1).
Analysis of the protein content of the cytosolic (SOD1) and mitochondrial (SOD2) antioxidant 
enzymes superoxide dismutase and CAT by RPPM suggested that the diminished TAC and SOD activ-
ities could be due to a very large reduction of the expression of SOD1 in vehicle-treated rd10 retinas 
(0.20 ± 0.03 a.u/ng protein, p = 0.004) (Fig.  5B). The content of SOD2 in vehicle-treated rd10 retinas 
(0.71 ± 0.06 a.u/ng protein) was similar to control retinas (0.61 ± 0.04 a.u/ng protein). Adalimumab 
increased the content of SOD1 (0.84 ± 0.11 a.u/ng protein, p = 0.001) and, to a lesser extent, of SOD2 
(0.90 ± 0.05 a.u/ng protein, p = 0.087) (Fig. 5B and Supplementary Table S1).
CAT activity was higher (p = 0.011) in vehicle-treated rd10 retinas (16 ± 2 U/mg protein) than in 
control retinas (10 ± 1 U/mg protein). CAT content had a tendency to increase (0.53 ± 0.05 a.u/ng pro-
tein, p = 0.15) compared to control retinas (0.39 ± 0.03 a.u/ng protein). Adalimumab had a tendency to 
reduce CAT activity (p = 0.078) but it did not have effect on CAT content (Fig. 5A,B, and Supplementary 
Table S1).
Discussion
TNFα inhibitors have been widely used for the treatment of different autoimmune disease, including 
ocular inflammatory disorders, with promising results33–35. Nevertheless, to our knowledge, we present 
the first study that evaluates the effect of TNFα inhibitors on the progression of the retinal degeneration 
in a murine model of RP. The results obtained in the present study revealed that intraperitoneal admin-
istration of Adalimumab, a recombinant human monoclonal antibody against TNFα , reduced retinal 
degeneration decreasing photoreceptor cell death and reactive gliosis at early stages of RP in rd10 mice.
Figure 5. Adalimumab improved antioxidant response at P18. Total antioxidant capacity (TAC), 
superoxide dismutase (SOD) and catalase (CAT) activities (a) and protein content of SOD1, SOD2 and CAT 
(b) were measured. Quantitation is shown in bar graphs. Values are the mean ± SEM of, at least, six retinas 
per group. Values that are significantly different are indicated by asterisks *p < 0.05, **p < 0.01, ***p < 0.001 
(Mixed linear model analysis).
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We used the rd10 mouse model of human autosomal recessive RP. This mutant mouse mimics the 
disease progression seen in some human conditions and offers an amenable therapeutic window. In gen-
eral, rod photoreceptors start to degenerate between P16 and P20, with a maximum cell death around 
P21 and P25. By P60, rods are undetectable and only cones remain2,36. Under our housing conditions, 
we observed that photoreceptor degeneration started around P15, with maximum TUNEL-positive 
cells around P18. This time point of maximum cell death agreed with results recently described by 
Arango-Gonzalez et al. (2014)37. In our study light intensity was higher (98–131 lux) than light intensity 
described by other authors (around 60 lux)38,39. Therefore, the early onset of photoreceptor degeneration 
could be explained by light conditions.
In the present study, we demonstrated that intraperitoneal injections of Adalimumab displayed a 
neuroprotective effect on photoreceptors survival at the onset of their death in rd10 mice. The admin-
istration of 3 mg/kg Adalimumab from P9 to P17 contributed to preserve retinal structure reducing the 
loss of photoreceptors at P18. Further, Adalimumab strongly reduced the number of TUNEL-positive 
cells in the ONL. Based on several studies using different animal models of RP, it has been suggested that 
apoptosis is playing a minor role in retinal degeneration37. However, non-apoptotic mechanisms seem 
to prevail as major contributors to cell death including accumulation of cGMP and activation of histone 
deacetylase (HDAC), PARP (PAR accumulation) and calpains40,41.
On the other hand, TNFα is considered both apoptotic and necroptotic inducer mainly through its 
binding to the receptor TNFR1. TNFα binds to TNFR1 leading to the recruitment of multiple proteins 
that can trigger different downstream pathways as activation of the transcription factor NF-κ B, MAPKs 
(mitogen-activated protein kinases), caspase 8 promoting cell survival, apoptosis or necroptosis, etc42. 
The two most extensively studied ways of necroptosis are initiated by TNFR1 and by PARP pathway. 
PARP pathway is initiated by overactivation of the DNA repair enzyme PARP-1, resulting in the massive 
synthesis of PAR and, eventually in necroptosis43. An evident controversial exists concerning to the link 
between TNFα and PARP pathway during necroptosis. Previously, PARP pathway has been suggested as 
a key element of TNFα -mediated necroptosis44. But other authors propose that TNFα -induced necrop-
tosis and PARP pathway represent distinct and independent routes to necroptosis45,46. In our previous 
study we found that TNFα inhibition did not prevent PAR accumulation but also increased it supporting 
the idea that PARP pathway was independent of TNFα -associated pathways in cultures of porcine ret-
ina exposed to Zaprinast25. In the current study we confirmed that there was an excessive nuclear PAR 
content in vehicle-treated rd10 mouse retinas that was effectively prevented by Adalimumab treatment. 
Therefore our results suggest that PARP activation is involved in TNFα -mediated photoreceptor cell 
death in rd10 mice. As described above, PARP activation could be consequence of excessive cGMP accu-
mulation that in turns would activate HDAC. PARP activation could be also consequent of the inflam-
matory process. We should confirm whether reduced inflammation could be the primary responsible for 
down regulation of PARP activity or could be secondary to reduced cell death. Thus, the mechanistic 
interpretation of these results is complicated and deserves further studies.
Upregulation of TNFα and activation of microglial cells are early events involved in photoreceptor 
death in murine models of RP11,47. We corroborated microglial activation and migration to outer retina 
in rd10 mice. However, we did not visualize Iba1-positive cells in the ONL in retinas from rd10 mice 
treated with Adalimumab. Thus, inhibition of TNFα reduced excessive microglial activation and migra-
tion of microglial cells to the outer layers. Microglial activation is a hallmark of neuroinflammation. It 
is associated with various neurodegenerative diseases including retinal degenerations10,48. Some ther-
apeutic approaches are designed to inhibit microglial activation. For instance, minocycline attenuated 
photoreceptor cell death in different animal models of retinal degeneration49,50 and improved vision in 
patients with diabetic macular edema51. Around 80 clinical trials are in progress to investigate the effect 
of minocycline in several pathologies including retinal degenerations (ClinicalTrials.gov, Identifiers: 
NCT02140164 and NCT01468844).
Recent studies showed that Adalimumab decreased glial cell activation (overexpression of GFAP) 
and preserved retinal organization in organotypic cultures of porcine neuroretina exposed to TNFα 52. 
Activated Müller cells can release antioxidants, growth factors and cytokines, including TNFα , contrib-
uting to retinal regeneration or degeneration. Müller cells are activated in models of RP resulting in 
overexpression of GFAP, activation of ERK (extracellular signal-regulated kinase), translocation of Müller 
cell bodies to the outer retina and thickening of their processes25,53. In the present study, Adalimumab 
tended to ameliorate GFAP overexpression in rd10 retinas.
Adalimumab specifically blocks the interaction of soluble TNFα , and to a lesser extent, transmem-
brane TNFα with its receptors, inhibiting downstream cellular signalling mechanisms21. We found that 
blocking TNFα tends to normalize the increased TNFα production, as described in other pathological 
situations54. TNFα blockade prevented the activation of signalling pathways involving the activation of 
p38 MAPK or NF-κ β 55,56. MAPKs such as ERK, JNK (c-Jun N-terminal kinase) and p38, are involved 
in many inflammatory and degenerative processes including retinal cell death53. Thus, we speculate that 
Adalimumab could attenuate the inflammatory process by interfering downstream signalling of TNFα , 
at the level of p38 MAPK or ERK activation. Further studies are needed to confirm this hypothesis.
Inflammation and oxidative stress are closely linked processes in several pathological situations. It 
has been widely suggested that oxidative stress contributes to the pathogenesis of RP in animal mod-
els and patients29–31. For instance, we previously found that RP patients present a reduced antioxidant 
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response9. In the current study we assessed whether down regulation of inflammation (TNFα and reac-
tive gliosis) induced by Adalimumab also influenced antioxidant response. Adalimumab improved anti-
oxidant defence machinery in rd10 mouse retinas. This treatment improved the total antioxidant capacity 
and total SOD activity probably by increasing SOD1 content in the retina of the rd10 mouse. It has 
been shown that SOD1 deficient mice are more sensitive to the damaging effects derived of oxidative 
insults57,58. Thus, SOD1 seems to be a key defender against oxidative damage in retina. It has been pre-
viously shown that Adalimumab can influence the antioxidant and oxidant status in other pathological 
situations such as psoriasis, rheumatoid arthritis, ankylosing spondylitis or uveitis32,59,60. For instance, 
Adalimumab is capable of upregulating SOD activity and downregulating catalase activity in mesen-
chymal stem cells from skin of patients with psoriasis59 and to restore glutathione (GSH) content and 
glutathione peroxidase activity in eyes of a uveitis experimental model60.
The retina is an organ with one of the highest energy demands per tissue weight due to the photo-
receptor cell metabolism. Glucose is metabolized through two major metabolic pathways: (1) glycolysis 
to obtain energy (ATP), reducing power (NADH) and pyruvate and (2) the pentose phosphate pathway 
(PPP) to obtain reducing power (NADPH) and ribose for nucleic acid biosynthesis. Under aerobic condi-
tions, pyruvate supplies ATP, precursors of certain amino acids as well as NADH through the citric acid 
cycle or Krebs cycle (TCA cycle). The NADH generated by the TCA cycle is fed into the mitochondrial 
oxidative phosphorylation (OXPHOS) pathway. During OXPHOS, electrons are transferred from elec-
tron donors to electron acceptors such as oxygen in redox reactions releasing energy and finally ATP. 
Photoreceptors contain a dense concentration of mitochondria in their inner segments that provides 
the ATP for the phototransduction processes mainly through the OXPHOS pathway61,62. Part of the 
oxygen consumed in OXPHOS is transformed to reactive oxygen species which are converted to H2O by 
antioxidant enzymes. However, a deficient antioxidant defence results in oxidative damage that initiates 
a cascade of events resulting in mitochondrial dysfunction and cell death63. In this study we corrobo-
rated the downregulation of OXPHOS pathway observed at the onset of photoreceptor degeneration in 
a Drosophila model expressing the equivalent of the most common RP-linked mutation, RhoP23H27. We 
also observed significant alterations in other energetic pathways as glycolysis, pentose phosphate pathway 
and β -oxidation indicating global energy depletion in rd10 retinas at P18. We also detected mitochon-
drial alterations in proteins related to its dynamics and structure supporting the results reported by other 
authors63,64. Adalimumab ameliorated energetic and metabolic dysfunction in rd10 mice.
It is tempting to speculate that Adalimumab or other anti-TNFα agents could be a promising therapy 
for RP and other retinal degenerations. However, further studies are needed to investigate in detail the 
molecular mechanisms involved in the neuroprotective effect of Adalimumab and its long-term effect.
Methods
Animals and treatment. rd10 mice were used as human model of autosomal recessive retinitis pig-
mentosa. Wild-type C57Bl6 mice with the same genetic background as rd10 mice were used as control. 
Mice were kept under a 12 hours light/dark cycle, humidity and temperature controlled and with food 
and water supplied ad libitum. All cages were placed on the lower shelf of an IVC rack with light illu-
minance of 115 ± 7 lux (95% CI: 98–131). Mice were housed in the Animal Facility of Unitat Central 
d’Investigació (UCIM) of Valencia University. This study was carried out in accordance with guidelines 
from the European Union Guidelines for the Care (European Union Directive (2010/63/EU) and the 
Use of Laboratory Animals. All animal procedures and protocols were approved (A1361179906177) and 
monitored by the Committee of Ethics in Research of the Faculty of Medicine, University of Valencia.
To determine the profile of retinal degeneration at early stages in our housing conditions, untreated 
rd10 and C57Bl6 mice were euthanized at P13, P15, P18 and P20. The eyes were rapidly removed and 
processed as described below.
To evaluate the effect of Adalimumab, each rd10 mouse received one intraperitoneal injection of 
Adalimumab (Humira, Abbot Laboratories) saline solution at 3 mg/kg every three days starting at P9 
and until P17. The dose of 3 mg/kg of Adalimumab was chosen based on previous studies with murine 
models of rheumatoid arthritis and uveitis60,65,66. No apparent side effects (e.g. opportunistic infections) 
were detected in animals treated with Adalimumab.
Control mice received the same volume of saline (vehicle) at the same time. At P18, treated and 
untreated rd10 mice and C57Bl6 mice were sacrificed. The eyes were rapidly removed and processed as 
described below.
ELISA assay. Retinas were homogenized in 20 mM Tris-HCl pH 7.4, 10 mM EDTA containing pro-
tease inhibitor cocktail (Complete Protease Inhibitor Cocktail; Roche, Basel, Switzerland) and 200 μ M 
phenylmethylsufloxifluoride (PMSF). The TNFα protein levels were estimated with a high sensitivity 
ELISA kit (eBioscience, Ireland, UK), according to the manufacturers’ instructions. Tissue TNFα levels 
were expressed as pg/mg protein.
Tissue processing. To obtain retinal sections, the eyes were rapidly removed and fixed in 4% fil-
tered paraformaldehyde for two hours at room temperature and cryoprotected in a sucrose gradient 
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(15–20–30%). Eyes were frozen embedded in OCT and 10 μ m sections were cut in a cryostat (Leica 
CM1900, Nussloch, Germany).
For biochemical determinations and gene expression analysis, retinas were isolated, placed immedi-
ately into the appropriate buffer and stored at − 80 °C.
Retinal immunohistochemistry and TUNEL assay. Immunofluorescent staining procedures 
were performed in 10 μ m cryosections. Sections were post-fixed in 4% filtered paraformaldehyde 
(Sigma-Aldrich, Madrid, Spain) in 0.1 M phosphate buffer pH 7.4 for 15 minutes at room temperature. 
Sections were pre-treated with citrate buffer pH 6.0 for epitope retrieval and incubated in blocking 
solution containing 5% normal goat serum, 1% bovine serum albumin and 0.25% Triton X-100 for 
one hour. Afterwards, they were incubated with primary antibody anti-PAR (1:200, Enzo Life Science, 
Madrid, Spain) as an indirect marker for PARP activity, anti-Iba1 (1:300, Wako Pure Chemical Industries 
Ltd., Osaka, Japan) and anti-GFAP (1:400, Sigma-Aldrich, Madrid, Spain) overnight at 4 °C. Sections 
were then incubated with the fluorescence-conjugated secondary antibody Alexa Fluor 647, 555 or 488 
(Invitrogen, Life Technologies, Madrid, Spain) for one hour at room temperature. After labelling, the sec-
tions were mounted in Fluoromount-G (Southern Biotechnology, Birmingham, AL, USA) and observed 
under a fluorescence or confocal microscope.
To evaluate cell death, the terminal deoxynucleotidyl transferase dUTP nick and labelling (TUNEL) 
assay was used as previously described67.
Microscopy and quantification. The retinal sections were examined under an Eclipse 80i micro-
scope (NIKON Instruments, Badhoevedorp, The Netherlands) or under a confocal microscope (Leica 
TCS SP5 Confocal microscope, Leica Microsistemas SLU, Barcelona, Spain) belonging to the Microscopy 
Unit of the IIS-La Fe (Valencia, Spain). ImageJ software was used to quantify the thickness and the num-
ber of rows of photoreceptor nuclei in the ONL, the number of TUNEL, PAR and Iba1-positive cells and 
the corrected fluorescence of GFAP.
We measured the ONL thickness of the entire retina normalized to the thickness of the inner nuclear 
layer (INL) to avoid the bias derived of the angle of the sectioning plane. Because the ONL thickness and 
the degenerative process in the rd10 model are not uniform and dependent upon location, we performed 
several measurements across the entire retina (from the nasal to the temporal retina) for each mouse. 
The normalized ONL thickness ratio is defined as the ONL thickness/INL thickness. At least five entire 
retinas were analysed per experimental group.
The number of TUNEL or PAR-positive cells was represented as the ratio between the number of 
TUNEL or PAR-positive cells in the ONL and the normalized ONL thickness ratio of each section.
To evaluate microglial activation we measured the migration index (M.I) which is defined as the 
number of Iba1-positive cells weighted according to the retinal layer where are located (M.I = ∑(number 
of Iba1-positive cells in each layer × layer weighted factor)/total number of Iba1-positive cells in the 
section. The layer weighted factor was 1 for ONL, 0.5 for outer plexiform layer (OPL) and 0.25 for INL.
Corrected fluorescence of GFAP was quantified as previously described25. TUNEL and PAR-positive 
cells, microglial migration index and the corrected fluorescence of GFAP were quantified from four 
non-adjacent sections of at least five retinas for each experimental group.
Isolation of total RNA and cDNA synthesis. Total RNA was isolated from frozen retina using 
RNeasy mini kit (Qiagen, Hilden, Germany) following the manufacturer’s protocol. Then, cDNA was 
synthesized starting from 1 μ g of RNA by reverse transcription using the GeneAmp Gold RNA PCR 
Reagent kit (Applied Biosystems, Carlsbad, CA, USA) following manufacturer’s instructions.
Quantitative real time PCR. The relative expression of TNFα and IL-6 was measured by real-time 
PCR using a commercial thermal-cycler (Applied Biosystems ViiATM 7 Real-Time PCR System; Life 
Technologies Corporation, Carlsbad, California, USA), TaqMan® gene expression assay (Mm00443260_
g1 (TNFα ) and Mm00446190_m1 (IL-6) and TaqMan® 2X PCR Master Mix (Applied Biosystems, Life 
Technologies Corporation, Carlsbad, California, USA). β 2 microglobulin (β 2m) gene (Mm00437762_
m1) was used as housekeeping gene.
Real-time PCR was performed with 1 cycle of 2 min at 50 °C, followed by 1 cycle of denaturation of 
10 min at 95 °C, continued by 40 cycles of 15 seconds denaturation at 95 °C and 60 seconds annealing at 
60 °C.
Evaluation of antioxidant response. Retinas were homogenized in 5 mM phosphate buffer pH 
7, 0.9% NaCl, 0.1% glucose, centrifuged at 10,000 × g (total antioxidant capacity (TAC) and catalase 
(CAT) activity) or 1,500 × g (superoxide dismutase (SOD) activity) for 15 minutes at 4 °C. Supernatants 
were used to determine TAC, CAT and SOD activities with commercial kits following Manufacturer´s 
Instructions (Cayman Chemical, Ann Arbor, MI, USA). Protein concentrations were measured by the 
bicinchoninic acid (BCA) protein assay. For total SOD activity assay one unit of SOD was defined as the 
amount of enzyme needed to exhibit 50% dismutation of the superoxide radical. For CAT activity assay 
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one unit was defined as the amount of enzyme that will cause the formation of 1.0 nmol of formaldehyde 
per minute at 25 °C. SOD and CAT activities were expressed as U/mg protein. Retinal TAC levels were 
expressed as nmol/mg protein.
Retinal content of SOD1 (cytosolic), SOD2 (mitochondrial) and CAT enzymes were measured as 
described below28.
Reverse Phase Protein Microarrays (RPPM). Thirty-six retinas were prepared for printing onto 
RPPM. Frozen retinas were grinded with liquid nitrogen and the tissue powder was extracted with 90 μ l 
of 50 mM Tris/HCl pH 8, containing 100 mM NaCl, 1 mM DTT, 1% (v/v) Triton X100, 0.1% SDS, 0.4 mM 
EDTA and a cocktail of protease (Roche) and phosphatase (Sigma) inhibitors. After protein extraction, 
samples were centrifuged at 15,000 g for 30 min at 4 °C. The protein concentration in the supernatants 
was determined with the Bradford reagent (Bio-Rad Protein Assay) using BSA as standard. For printing 
and processing, samples were diluted in PBS to a final protein concentration of 0.75 μ g/μ l. Serially diluted 
protein extracts (0–1 μ g/μ l) derived from HCT-116 and OVCAR8 carcinoma cells were also prepared to 
assess printing quality and the linear response of protein recognition by the antibodies used28. A solution 
of BSA (1 μ g/μ l) was also prepared for printing as internal negative control. Approximately, 1 nl volume 
of each sample was spotted in duplicate onto nitrocellulose-coated glass slides (FAST Slides, Scheleicher 
& Schuell BioScience, Inc.) using a BioOdyssey Calligrapher MiniArrayer printer (Bio-Rad Laboratories, 
Inc.) equipped with a solid pin (MCP310S) at constant humidity and temperature28. After printing, 
arrays were allowed to dry and further blocked in PBS-T containing 5% skimmed milk. After, the arrays 
were incubated overnight at 4 °C with the indicated concentrations of the following highly specific pri-
mary monoclonal antibodies (mAbs): β -F1-ATPase (0,4 μ g/ml) and anti-Hsp60 (4 ug/ml)28; anti-LDHA 
(4 μ g/ml)68; anti-GAPDH (1/20000; Abcam), anti-complex II subunit B (SDHB, 1/500; Invitrogen), 
anti-complex III subunit Core 2 (Core2, 1/1000; Mitosciences), anti-catalase (1/5000; Sigma-Aldrich), 
anti-complex IV subunit II (COXII, 1/100; Abcam), anti-complex I Ndufs3 (1/200; Abcam), anti-β -actin 
(1/5000;Sigma), anti-OPA1 (1/500; BD Transduction Lab) and the indicated concentrations of the fol-
lowing polyclonal antibodies: anti-HADHA (1/200; Abcam), anti-SOD1 (1/200; Santa-Cruz), anti-SOD2 
(1/200; Abcam) and anti-G6PDH (1/500; Thermo Scientific). After incubation, the arrays were processed 
and revealed as previously described28. The mean fluorescent intensity of the spots was quantified using 
FIJI software (N.I.H., USA) and converted into arbitrary units of expressed protein/ng of total protein 
in the tissue extract using the expression obtained in the linear plot of the HCT116 cell line as standard 
(see Supplementary Figure S1).
Statistical analyses. Statistical analysis was performed using R software (version 3.1.2). Comparisons 
between different age categories were performed using Mann-Whitney U. A generalized least squares 
model was fitted to the log-transformed TNFα protein values to assess differences between the two 
experimental groups and also the effect of Adalimumab (ADA). Linear models were used to assess the 
association between ADA and the two experimental groups with the different response variables. To 
account for the non-independence of observations in the case of repeated measures per sample, a ran-
dom intercept was added to the linear models with the variable sample as random factor. P values 
for the mixed linear models were computed using Satterthwaite approximation to degrees of freedom. 
Estimations for each variable in a linear mixed model are interpreted similarly than estimations from 
an ordinary linear model, that is, in an additive way. Negative values indicated a negative effect of being 
rd10 or having received Adalimumab. And positive values indicated a positive effect. Some response 
variables were logarithmically transformed to avoid negative values for the estimated control values. 
Result tables from the models are shown in Supplementary Table S1. Reverse Phase Protein Microarrays 
were analysed by One-way ANOVA and Newman-Keuls post-test. A p-value < 0.05 was considered sta-
tistically significant.
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